Background The highest number of COVID-19 cases in Italy have been reported in
Lombardy, a region in northern Italy. We aimed to analyse the course of severe acute …

Mehta and colleagues1 postulate that hyperinflammation in coronavirus disease 2019
(COVID-19) could be a driver of severity that is amenable to therapeutic targeting since …

Background COVID-19 can induce a hyperinflammatory state, which might lead to poor
clinical outcomes. We aimed to assess whether patients with a systemic rheumatic disease …

Studies have revealed that patients with immunemediated inflammatory diseases, especially
those on immunomodulatory medication, have attenuated immunogenicity to COVID-19 …

Objectives To update the EULAR points to consider (PtCs) on the use of immunomodulatory
therapies in COVID-19. Methods According to the EULAR standardised operating …

Background Many individuals take long-term immunosuppressive medications. We
evaluated whether these individuals have worse outcomes when hospitalised with COVID …

Comment www. thelancet. com/rheumatology Vol 3 March 2021 e167 antibodies. Moreover,
1559 (95%) patients were taking at least one of the following drugs: low-dose steroids …

COVID-19 is presenting an unparalleled challenge for clinicians. In critical cases, the
combination of severe inflam mation, systemic coagulopathy, and acute respiratory failure …

Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …

After its emergence in December 2019 in Wuhan, China, the COVID-19 outbreak has now
one of its main epicentres in Lombardy (Italy), with more than 50 000 confirmed cases and …